Bone marrow endothelial progenitors are defective in systemic sclerosis

Arthritis and Rheumatism

Volumn 54, Issue 8, 2006, Pages 2605-2615

  Del Papa, Nicoletta ^a,e   Quirici, Nadia ^b   Soligo, Davide ^a   Scavullo, Cinzia ^b   Cortiana, Michela ^a   Borsotti, Chiara ^b   Maglione, Wanda ^a   Comina, Denise P ^a   Vitali, Claudio ^c   Fraticelli, Paolo ^d   Gabrielli, Armando ^d   Cortelezzi, Agostino ^a   Lambertenghi Deliliers, Giorgio ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b FATEBENEFRATELLI HOSPITAL   (Italy)

^c Villamarina Hospital   (Italy)

^d UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^e ISTITUTO ORTOPEDICO GAETANO PINI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD133 ANTIGEN; CD14 ANTIGEN; CD19 ANTIGEN; CD3 ANTIGEN; CD45 ANTIGEN; ENDOGLIN; GLYCOPHORIN A; NERVE GROWTH FACTOR RECEPTOR; STEM CELL FACTOR RECEPTOR; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ARTICLE; BONE MARROW CELL; CELL COMPARTMENTALIZATION; CELL DIFFERENTIATION; CELL GROWTH; CELL LINEAGE; CONTROLLED STUDY; ENDOTHELIUM CELL; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; MAJOR CLINICAL STUDY; MESENCHYMAL STEM CELL; MICROCIRCULATION; MICROENVIRONMENT; PATHOPHYSIOLOGY; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; SCLERODERMA; STROMA CELL; SYSTEMIC SCLEROSIS;

ADULT; AGED; ANTIGENS, CD; ANTIGENS, CD45; BONE MARROW CELLS; CELL DIFFERENTIATION; CELLS, CULTURED; ENDOTHELIAL CELLS; FEMALE; FLOW CYTOMETRY; GLYCOPROTEINS; HUMANS; MALE; MESENCHYMAL STEM CELLS; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDES; SCLERODERMA, SYSTEMIC;

EID: 33746982540     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.22035     Document Type: Article

References (53)

1. Murasawa S, Asahara T. Endothelial progenitor cells for vasculogenesis. Physiology (Bethesda) 2005;20:36-42.
2. Hristov M, Weber C. Endothelial progenitor cells: characterization, pathophysiology, and possible clinical relevance. J Cell Mol Med 2004;8:498-508.
3. Shintani S, Murohara T, Ikeda H, Ueno T, Hoenma T, Katioh A, et al. Mobilization of endothelial progenitor cells in patients with acute myocardial infarction. Circulation 2001;103:2776-9.
4. Gill M, Dias S, Hattori K, Rivera ML, Hicklin D, Witte L, et al. Vascular trauma induces rapid but transient mobilization of VEGFR2(+)AC133(+) endothelial precursor cells. Circ Res 2001;88:167-74.
5. Vasa M, Fichtischerer S, Aicher A, Adler K, Urbich C, Martin H, et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res 2001;89:e1-7.
6. Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, Quyyumi AA, et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 2003:348: 593-600.
7. + and endothelial progenitor cells in patients with various degrees of congestive heart failure. Circulation 2004;110:1209-12.
8. Loomans CJ, de Koning EJ, Staal FJ, Rookmaaker MB, Verseyden C, de Boer HC, et al. Endothelial progenitor cell dysfunction: a novel concept in the pathogenesis of vascular complications of type 1 diabetes. Diabetes 2004;53:195-9.
9. Werner N, Kosiol S, Schiegl T, Ahlers P, Walenta K, Link A, et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 2005;353:999-1007.
10. Herrick AL. Vascular function in systemic sclerosis. Curr Opin Rheumatol 2000;12:527-33.
11. LeRoy EC. Systemic sclerosis: a vascular perspective. Rheum Dis Clin North Am 1996;22:675-94.
12. Flavahan NA, Flavahan S, Mitra S, Chotani MA. The vasculopathy of Raynaud's phenomenon and scleroderma. Rheum Dis Clin North Am 2003;29:275-91.
13. Del Papa N, Colombe G, Fracchiolla N, Moronetti LM, Ingegnoli F, Maglione W, et al. Circulating endothelial cells as a marker of ongoing vascular disease in systemic sclerosis. Arthritis Rheum 2004;50:1296-304.
14. Kuwana M, Okazaki Y. Yasuoka H, Kawakami Y, Ikeda Y. Defective vasculogenssis in systemic sclerosis. Lancet 2004;364: 603-10.
15. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
16. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T. Medsger TA, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogeresis. J Rheumatol 1988;15:202-5.
17. Ferri C, Valentini G, Cozzi F, Sebastiani M, Michelassi C, La Montagna G, et al. Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (Baltimore) 2002;81:139-53.
18. Valentini G, Della Rossa A, Bombardieri S, Bencivelli W, Silman AJ, D'Angelo S, et al. European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes. Ann Rheum Dis 2001;60:592-8.
19. Valentini G, Bencivelli W, Bombardieri S, D'Angelo S, Della Rossa A, Silman AJ, et al. European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. III. Assessment of the construct validity of the preliminary activity criteria. Ann Rheum Dis 2003;62:901-3.
20. Medsger TA Jr, Steen VD. Classification, prognosis. In: Clements PJ, Furst DE, editors. Systemic sclerosis. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 1996. p. 51-79.
21. + cells. Br J Haematol 2001;115:186-94.
22. Cordell JL, Falini B, Erber WN, Ghosh AK, Abdulaziz Z, MacDonald S, et al. Immunoenzymatic labelling of monoclonal antibody using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem 1984;32:219-29.
23. Quirici N, Soligo D, Bossolasco P, Servida F, Lumini C, Deliliers GL. Isolation of bone marrow mesenchymal stem cells by anti-nerve growth facto: receptor antibodies. Exp Hematol 2002;30: 783-91.
24. Castro-Malaspina H, Gay RE, Resnick G, Kapoor N, Mayers P, Chiarirei D, et al. Characterization of human bone marrow fibroblast colony-forming cells (CFU-F) and their progeny. Blood 1980;56:289-301.
25. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999;284:143-7.
26. DiGirolamo CM, Stokes D, Colter D, Phinney G, Class R, Prockop DJ. Propagation and senescence of human marrow stromal cells in cuhure: a simple colony-forming assay identifies samples with the greatest potential to propagate and differentiate. Br J Haematol 1999;107:275-81.
27. Stanford CM, Jacobson PA, Eanes ED, Lembke MA, Midura LJ. Rapid forming apoptotic mineral in an osteoblastic cell line (UMR 106-01 BSP). J Biol Chem 1995;270:9420-8.
28. Chang J, Morgenstern G, Coutinho LH, Scarffe JH, Carr T, Deakin DP, et al. The use of bone marrow cells grown in long-term bone marrow cultures of autologous BMT in acute leukaemia: an update. Bone Marrow Transplant 1989;4:5-9.
29. Rafii S. Circulating endothelial precursors: mystery, reality, and promise. J Clin Invest 2000;105:17-9.
30. + mesenchymal stem cells [abstract]. Blood 2004;104:2333.
31. Distler O, Del Rosso A, Giacomelli R, Cipriani P, Conforti ML, Guiducci S, et al. Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factors are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers. Arthritis Res 2002;4:R11.
32. Choj JJ, Min DJ, Cho ML, Min SY, Kim SJ, Lee SS, et al. Elevated vascular endothelial growth factor in systemic sclerosis. J Rheumatol 2003;30:1529-33.
33. Dor Y, Djonov V, Abramovitch R, Itin A, Fishman GI, Carmeliet P, et al. Conditional switching of VEGF provides new insights into adult neovascularization and pro-angiogenic therapy. EMBO J 2002;21:1939-47.
34. Distler O, Distler JH, Schaid A, Acker T, Hirth A, Rethage J, et al. Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis. Circ Res 2004;95:109-16.
35. Davani S, Marandin A, Mersin N, Rover B, Kantelip B, Herve P, et al. Mesenchymal progenitor cells differentiate into an endothelial phenotype, enhance vascular density and improve heart function in a rat cellular cardiomyoplasty model. Circulation 2003;108: 11253-8.
36. Gojo S, Gojo N, Takeda Y, Mori T, Abe H, Kyo S, et al. In vivo cardiovasculogenesis by direct injection of isolated adult mesenchymal stem cells. Exp Cell Res 2003;288:51-9.
37. Dong C, Zhu S, Wang T, Yoon W, Li Z, Alvarez RJ, et al. Deficient Smad7 expression: a putative molecular defect in scleroderma. Proc Natl Acad Sci U S A 2002;19:3908-13.
38. Ribatti D, Cantatore FP, Vacca A, D'Amore M, Ria R, Roncali R, et al. Systemic sclerosis stimulates angiogenesis in the chick embryo chorioallantoic membrane. Clin Rheumatol 1998;17: 115-20.
39. Peichev M, Naiyer AJ, Pereira D, Zhu Z, Lane WJ, Williams M, et al. Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood 2000;95:952-58.
40. Sgonc R, Gruschwitz MS, Boeck G, Sepp N, Gruber J, Wick G. Endothelial cell apoptosis in systemic sclerosis is induced by antibody-dependent cell-mediated cytotoxicity via CD95. Arthritis Rheum 2000;43:2550-62.
41. Lunardi C, Bason C, Navone R, Millo E, Damonte G, Corrocher R, et al. Systemic sclerosis immunoglobulin G autoantibodies bind the human cytomegalovirus late protein UL94 and induce apoptosis in human endothelial cells. Nat Med 2000;6:1183-6.
42. Claman HN, Giorno RC, Seibold JR. Endothelial and fibroblastic activation in scleroderma: the myth of the "uninvolved skin." Arthritis Rheum 1991;34:1495-501.
43. Stratton RJ, Coghlan JG, Pearson JD, Burns A, Sweny P, Abraham DJ, et al. Different patterns of endothelial cell activation in renal and pulmonary vascular disease in scleroderma. QJM 1998; 91:561-6.
44. Kraling BM, Jimenez SA, Sorger T, Maul GG. Isolation and characterization of microvascular endothelial cells from the adult human dermis and from skin biopsies of patients with systemic sclerosis. Lab Invest 1994;71:745-54.
45. Majewski S, Hunzelmann N, Johnson JP, Jung C, Mauch C, Ziegler-Heitbrock HW, et al. Expression of intercellular adhesion molecule-1 (ICAM-1) in the skin of patients with systemic scleroderma. J Invest Dermatol 1991;97:667-71.
46. 2 integrins, intercellular adhesion molecule 1, and endothelial leukocyte adhesion molecule 1 in the skin of patients with systemic sclerosis of recent onset. Arthritis Rheum 1992;35:290-8.
47. Denton CP, Bickerstaff MC, Shiwen X, Carulli MT, Haskard DO, Dubois RM, et al. Serial circulating adhesion molecule levels reflect disease severity in systemic sclerosis. Br J Rheumatol 1995;34:1048-54.
48. Veale DJ, Kirk G, McLaren M, Belch JJ. Clinical implications of soluble intercellular adhesion molecule-1 levels in systemic sclerosis. Br J Rheumatol 1998;37:1227-8.
49. Abraham DJ, Varga J. Scleroderma: from cell and molecular mechanisms to disease models. Trends Immunol 2005;26:587-95.
50. Dignat-George F. Sampol J. Circulating endothelial cells in vascular disorders: new insights into an old concept. Eur J Haematol 2000;65:215-20.
51. Kang HJ, Kim HS, Zhang SY, Park W, Cho HJ, Koo BK, et al. Effects of intracoronary infusion of peripheral blood stem-cells mobilised with granulocyte-colony stimulating factor on left ventricular systolic function and restenosis after coronary stenting in myocardial infarction: the MAGIC cell randomised clinical trial. Lancet 2004;363:751-6.
52. Vasa M, Fichtlscherer S, Adler K, Aicher A, Martin H, Zeiher AM, et al. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation 2001;103:2885-90.
53. Huang P, Li S, Han M, Xiao Z, lang R, Hang ZC. Autologous transplantation of granulocyte colony-stimulating factor mobilized peripheral blood mononuclear cells improves critical limb ischemia in diabetes. Diabetes Care 2005;28:2155-60.